| Biosimilars will contribute to multiple-source biologics markets when they are allowed to compete fairly with their reference products. |
| There are several different types of disparagement and misinformation directed against biosimilars, individually and collectively, that are impeding their ability to contribute to a sustainable multiple-source biologics market. |
| Disparagement and misinformation about biosimilars can be countered by balanced educational outreach across stakeholders, appropriate regulatory oversight, and use of enforcement powers already granted to government agencies. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.